Abstract
Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Current Psychopharmacology
Title:Interrelation of Major Depression and Antidepressant Transcriptomics
Volume: 1
Author(s): Jurgen Zschocke, Nils Christian Gassen and Theo Rein
Affiliation:
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Abstract: Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Export Options
About this article
Cite this article as:
Zschocke Jurgen, Christian Gassen Nils and Rein Theo, Interrelation of Major Depression and Antidepressant Transcriptomics, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040284
DOI https://dx.doi.org/10.2174/2211556011201040284 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development
Current Drug Targets Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity
Current Topics in Medicinal Chemistry Poxvirus Cancer Therapy
Recent Patents on Anti-Infective Drug Discovery BRCA-FA Pathway as a Target for Anti-Tumor Drugs
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
Current Medicinal Chemistry The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine RAGE as a Receptor of HMGB1 (Amphoterin): Roles in Health and Disease
Current Molecular Medicine SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Current Molecular Medicine Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Identification of WHO II/III Gliomas by 16 Prognostic-related Gene Signatures using Machine Learning Methods
Current Medicinal Chemistry Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Tumor Initiating Cells
Current Pharmaceutical Biotechnology